



Anti-BCL9 (aa 1036-1135) polyclonal antibody (DPAB-DC2714)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Antigen Description	BCL9 is associated with B-cell acute lymphoblastic leukemia. It may be a target of translocation in B-cell malignancies with abnormalities of 1q21. Its function is unknown. The overexpression of BCL9 may be of pathogenic significance in B-cell malignancies.
Immunogen	BCL9 (NP_004317, 1036 a.a. ~ 1135 a.a) partial recombinant protein with GST tag. The sequence is DDDSPPARSPNLPSMNNMPGMGINTQNPRISGPNPVVPMPTLSPMGMTQPLSHSNQMPSP NAVGNIPPHGVPMGPGLMSHNPIMGHGSQEPPMVPQGRM
Source/Host	Mouse
Species Reactivity	Human
Conjugate	Unconjugated
Applications	WB (Recombinant protein), ELISA,
Size	50 µl
Buffer	50 % glycerol
Preservative	None
Storage	Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.

GENE INFORMATION

Gene Name [BCL9 B-cell CLL/lymphoma 9 \[Homo sapiens \(human\) \]](#)

Official Symbol	BCL9
Synonyms	BCL9; B-cell CLL/lymphoma 9; LGS; B-cell CLL/lymphoma 9 protein; bcl-9; protein legless homolog; B-cell lymphoma 9 protein;
Entrez Gene ID	607
Protein Refseq	NP_004317
UniProt ID	A0A024QYY4
Chromosome Location	1q21
Pathway	Regulation of Wnt-mediated beta catenin signaling and target gene transcription; Signaling by Wnt; Wnt Signaling Pathway NetPath; formation of the beta-catenin:TCF transactivating complex.
Function	beta-catenin binding; protein binding;